These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 14558209)
1. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary]. Damber JE Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209 [No Abstract] [Full Text] [Related]
2. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? Barry MJ; Mulley AJ J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451 [No Abstract] [Full Text] [Related]
3. Is screening for prostate cancer the current gold standard?--"yes". Lange PH Eur J Cancer; 1997 Mar; 33(3):354-6. PubMed ID: 9155516 [No Abstract] [Full Text] [Related]
4. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. Belpomme D; Irigaray P J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186 [No Abstract] [Full Text] [Related]
5. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues. Ito K Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638 [No Abstract] [Full Text] [Related]
6. Best screening tests for prostate cancer. Moul JW West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692 [No Abstract] [Full Text] [Related]
7. [PSA based screening for prostatic cancer]. Johansen TE Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357 [No Abstract] [Full Text] [Related]
8. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. Hamilton RJ; Platz EA; Freedland SJ J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913 [No Abstract] [Full Text] [Related]
9. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]. Zhao XJ; Kong XB; Wang WH Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882 [TBL] [Abstract][Full Text] [Related]
10. Is an improved PSA screening test in sight? Savage L J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529 [No Abstract] [Full Text] [Related]
11. Does screening with prostate/specific antigen improve outcomes? Ohrt D Minn Med; 1996 Apr; 79(4):50-1. PubMed ID: 8637494 [No Abstract] [Full Text] [Related]
12. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers. Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244 [No Abstract] [Full Text] [Related]
13. [Mass screening for prostate cancer in Nagano]. Ishizuka O; Satoh T; Kobayashi S; Nishizawa O Hinyokika Kiyo; 2001 Nov; 47(11):769-72. PubMed ID: 11771167 [TBL] [Abstract][Full Text] [Related]
14. Is screening for prostate cancer the current gold standard?--"no". Kramer BS; Gohagan JK; Prorok PC Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515 [No Abstract] [Full Text] [Related]
15. Prostate-specific antigen: a misused and maligned prostate cancer biomarker. Thompson IM; Tangen CM; Kristal AR J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671 [No Abstract] [Full Text] [Related]
16. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care. Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323 [No Abstract] [Full Text] [Related]
17. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Perrin P Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016 [No Abstract] [Full Text] [Related]
18. Application of prostate-specific antigen in prostate cancer. Liang SL MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558 [No Abstract] [Full Text] [Related]